ArticleRSC advances2026
Fabrication of healable and flame-retardant polymer films based on phosphonate dynamic covalent crosslinking networks.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphoester linkages are attractive not only for flame retardancy but also dynamic covalent networks (DCNs) while preparing self-healing materials. However, thermal activation of these linkages may induce irreversible structural changes by condensation or volatile product evolution. In this study, phosphonate crosslinkages were investigated as an alternative dynamic linkage and directly compared with phosphoester crosslinkages in polymer networks based on poly(2-hydroxyethyl methacrylate) (PHEMA). Phosphoester- and phosphonate-crosslinked films were prepared using 2-methoxy-2-oxo-1,3,2-dioxaphosphorane or 2-methyl-2-oxo-1,3,2-dioxaphosphorane, respectively. Upon thermal treatment, the phosphoester-based DCN exhibited irreversible changes in mechanical properties and mass loss, resulting from the evolution of volatile byproducts during transesterification. Conversely, the phosphonate-based DCN maintained its mechanical properties and catalyst-free dynamic bond exchangeability with an activation energy of 122.0 kJ mol
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.